BMI's Executive Summary

[TOP]

The United Arab Emirates may not be the largest pharmaceutical market in the Middle East and Africa (MEA), but it possesses several advantages that make it an attractive prospect. The drug market is estimated to be worth US$0.9bn in 2007 and it should display a strong CAGR of 10% to reach a value of US$1.45bn by 2012. Drivers of growth will be increasing public and private wealth fuelled by the oil boom, and a strong healthcare infrastructure that ensures high-tech treatments are always available. A friendly regulatory environment and absence of significant local competitors are other factors influencing a growing number of small research firms locating to the country.

The government is keen to attract foreign investment and diversify the country's economy, which is highly reliant on oil. To this end, the government has identified the pharmaceutical and healthcare industries as important industries to develop. Authorities have created two notable free zones to attract foreign investment. DuBiotech is aimed at developing the UAE's biotech industry, while Dubai Healthcare City (DHCC) should enhance the country's healthcare system and should enhance the UAE's reputation as a centre for premium healthcare, encouraging growth as a medical tourism destination.

Meanwhile, the pharmaceutical manufacturing business is in danger of getting left behind the fastdeveloping biotech and healthcare sectors. The largest domestic player, Julphar, only generates 7% of sales in the UAE. A wealthy population with a preference for novel therapies ensures there is a high demand for imports of patented drugs. Consequently, the pharmaceutical trade balance is in the red and expected to become more negative over the five year forecast period, although a relaxation of the rules governing foreign ownership of companies should serve to boost investment in the local manufacturing industry.

For Q108 BMI has overhauled its business environment ratings methodology. Under the new system, the UAE is placed first in the Middle East and Africa (MEA) region, with a lead of eight points over second place Turkey. With a smaller pharmaceutical market than Turkey or Saudi Arabia, the UAE relies on a sound regulatory regime, a stable, Western-friendly political leadership and favourable country structure to boost its score.

Contents

[TOP]

Chapter 1 - Executive Summary

United Arab Emirates Pharmaceuticals & Healthcare Industry SWOT

United Arab Emirates Political SWOT

United Arab Emirates Economic SWOT

United Arab Emirates Business Environment SWOT

Business Environment Ranking

Table: Business Environment Ranking: Middle East & Africa

Business Environment Ranking

Economics - Long-Term Risk

Politics - Long-Term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 2 - Market Overview

Regulatory Environment

Intellectual Property Developments

Pricing & Reimbursement Issues

Prescribing Practices

Health Insurance

Expatriate Worker Insurance

Chapter 3 - Industry Trends & Developments

Pharmaceutical Sector

Company Developments

Healthcare Sector

DuBiotech

Tobacco-Related Illness

Chapter 4 - Industry Forecast Scenario

Overall Market Forecast

Table: Drug Market Trends

Key Growth Factors - Pharmaceuticals & Healthcare Industry

Macroeconomic Scenario

Table: Economic Indicators

Prescription & OTC Market Forecasts

Table: Prescription Drug Market Trends

Table: OTC Drug Market Trends

Generics Market Forecast

Table: Generic Market Indicators

Imports/Exports Forecast

Table: Pharmaceutical Import/Export Trends

Other Healthcare Forecasts

Table: Other Healthcare Forecast Data

Key Risks To BMI's Forecast Scenario

Chapter 5 - Competitive Landscape

Performance Summary: The Five Leading Multinationals

Chapter 6 - Company Monitor

Profiles: Leading Foreign Companies

Novartis

Johnson & Johnson (J&J)

Abbott Laboratories

Indigenous Manufacturer

Gulf Pharmaceutical Industries (Julphar)

Chapter 7 - BMI Forecast Modelling

How We Generate Our Industry Forecasts

Technical Process

Pharmaceutical Industry

Sources

Chapter 8 - Appendix: Regional Demographic

The Long View: Data Over The Economic

Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Market Size, GDP, US$bn

Chapter 9 - Country Snapshot: UAE Demographic

Section 1: Population:

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption and Stratification

Competitive Landscape for Middle East & Africa Pharmaceuticals and Healthcare: Sample of Companies Ranked

[TOP]

Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.

Network of Middle Eastern and African Pharmaceutical & Healthcare Sources

[TOP]

BMI's Middle Eastern & African Pharmaceutical & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceutical & healthcare industry associations, chambers of commerce and company reports. Information sources include: